January 2024

During our previous conversation about Gujarat Themis Biosyn, the stock was priced at approximately 817 (adjusted to 160 after the split), hovering just below its 52-week high. At that time, we identified a strategic entry point, slightly below the apparent breakout level, providing an advantageous opportunity. Presently, the stock has surged to 286 levels, resulting… Read more